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Convincing evidence indicates that statins stimulate apoptotic cell death in several types of proliferating tumor
cells in a cholesterol-lowering-independent manner. However, the relationship between apoptosis and autophagy
in lymphoma cells exposed to statins remains unclear. The objective of this study was to elucidate the potential
involvement of autophagy in fluvastatin-induced cell death of lymphoma cells. We found that fluvastatin treatment
enhanced the activation of pro-apoptotic members such as caspase-3 and Bax, but suppressed the activation of
anti-apoptotic molecule Bcl-2 in lymphoma cells including A20 and EL4 cells. The process was accompanied by
increases in numbers of annexin V alone or annexin V/PI double positive cells. Furthermore, both autophagosomes
and increases in levels of LC3-II were also observed in fluvastatin-treated lymphoma cells. However, apoptosis in
fluvastatin-treated lymphoma cells could be blocked by the addition of 3-methyladenine (3-MA), the specific inhibitor
of autophagy. Fluvastatin-induced activation of caspase-3, DNA fragmentation, and activation of LC3-II were
blocked by metabolic products of the HMG-CoA reductase reaction, such as mevalonate, farnesyl pyrophosphate (FPP)
and geranylgeranyl pyrophosphate (GGPP). These results suggest that autophagy contributes to fluvastatin-induced
apoptosis in lymphoma cells, and that these regulating processes require inhibition of metabolic products of the
HMG-CoA reductase reaction including mevalonate, FPP and GGPP.
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Malignant lymphoma (ML), a heterogeneous disease with
highly variable clinical course and prognosis, is the most
common type of adult leukemia [1]. Most patients with
malignant lymphomas in clinical course are aggressive and
soon after diagnosis require intensive treatment [2]. Both
the defective balance between pro- and anti-apoptotic
molecules and aberrant up-regulation of pro-survival
signals had been shown to be related to resistance of
malignant lymphoma cells to radiation therapy and
chemotherapy [3]. Despite therapies with purine ana-
logs, glucocorticoids, alkylating agents, or monoclonal* Correspondence: qixufeng@jnu.edu.cn; kim6@yonsei.ac.kr
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reproduction in any medium, provided the orantibodies appears to be effective, less toxic and more
effective drugs are needed to development.
Statins, the inhibitors of 3-hydroxy-3-methyl glutaryl
coenzyme A (HMG-CoA) reductase, are used to treat
hypercholesterolemia. Convincing evidence from both
in vitro and in vivo data has demonstrated that statins
exert pleiotropic actions beyond their lipid-lowering
effects, including immune regulation [4] and cancer
prevention [5,6]. Statins have been demonstrated to
induce cell cycle arrest and cell death in various cancer
cells such as multiple myeloma cells [7], pancreatic
cancer cells [8], non-small lung cancer cells [9], walden-
strom macroglobulinemia cells [10], and breast cancer
MCF-7 cells [11].
Cell deaths include programmed cell death (PCD) and
necrosis. Among them, apoptosis is the common form
of PCD in multicellular organisms, which appears to be
morphologically characterized by cell shrinkage, chromatin
condensation, and formation of apoptotic bodies. These
processes are influenced by the unbalance of pro- andThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12]. The main biochemical features of apoptosis include
caspase activation and DNA fragmentation [12-14].
Apoptosis is induced by various physiological or toxic
stimuli such as chemotherapeutic drugs, DNA damage,
ultraviolet irradiation, oxidative stress and endoplasmic
reticulum stress [13,15].
Except for apoptosis, another cell death model, autoph-
agy, is a bulk degradation system for cytoplasmic compo-
nents including organelles through the lysosomal pathway,
and is characterized by the formation of autophagosomes
[16]. Autophagosomes ultimately fuse with lysosomes,
thereby generating single-membrane autophagolysosomes
and degrading their content. In addition to its basic role in
the turnover of proteins and organelles, autophagy has
multiple physiological and pathophysiological functions
including roles in cell differentiation, immune defense,
and cell death [16].
Recent studies have demonstrated that there is a close
relationship between autophagy and apoptosis in different
cell types or under different pathological conditions. The
complex formed by S100 calcium-binding protein A8/A9
can induce apoptosis and autophagy in several cancer
cells, such as MCF-7, SHEP and HEK-293. However,
S100A8/A9-induced cell death could be partially blocked
by the inhibition of autophagy [17]. On the other hand,
autophagy can be extensively induced in normal mouse
B cells or WEHI-231 B cell line upon induction of BCR
ligation-induced apoptosis [18]. These previous reports
indicated that the relationship between apoptosis and
autophagy varies under different conditions. We previously
demonstrated that statins can induce apoptotic cell
death in lymphoma cells by stimulating caspase3-related
pathways [19]. However, the potential involvement of
autophagy in statin-induced apoptosis remains unclear.
Here, we reported that fluvastatin induced apoptosis in
lymphoma cells by activating pro-apoptotic signals
including caspase-3 and Bax and by suppressing anti-
apoptotic signal, Bcl2. Furthermore, autophagy was also
observed in fluvastatin-treated lymphoma cells. Inter-
estingly, autophagy contributed to fluvastatin-induced
apoptosis in lymphoma cells.
Materials and methods
Reagents
Fluvastatin (sodium salt, C24H25FNNaO4) was purchased
from Calbiochem (La Jolla, CA, USA). Propidium iodide
(PI), mevalonate (Mev), farnesyl pyrophosphate ammonium
salt (FPP), geranylgeranyl pyrophosphate ammonium salt
(GGPP), coenzyme Q10 (CoQ10), and 3-Methyladenine
(3-MA) were purchased from Sigma-Aldrich Co. (St. Louis,
MO, USA). Antibodies against cleaved caspase-3, Bax,
Bcl2, LC3, β-actin and HRP-conjugated goat anti-rabbit
IgG were from Cell Signaling Technology (Beverly, MA,USA). A sensitive western blotting luminal reagent was
obtained from Santa Cruz Biotechnology Inc. (Santa
Cruz, California, USA).
Cell culture
A20 and EL4 lymphoma cells (Korean Cell Line Bank,
Seoul, Korea) were cultured in RPMI 1640 medium (Bio-
Whittaker Inc., Walkersville, MD, USA) containing 10%
fetal bovine serum (FBS), 100 U · mL-1 penicillin, and
100 μg · mL-1 streptomycin (all from BioWhittaker Inc.,
Walkersville, MD, USA) at 37°C in a 5% CO2 incubator. In
experiments described below, the medium was exchanged
for RPMI 1640 medium containing 2% FBS.
Annexin V (AV)/propidium iodide (PI) double staining
Phosphatidylserine on the cell surface was detected with
Annexin V-FITC Apoptosis Detection Kit (BD Biosciences,
NJ, USA) according to the manufacturer’s instructions. In
brief, cells were incubated with fluvastatin at concentra-
tions ranging from 0 to 10 μM for 24 h. Collected cells
were incubated with FITC-conjugated annexin V and PI
for 20 min at room temperature in the dark. The cells were
washed with ice-cold PBS, resuspended, and a fraction of
the suspension was smeared on a slide. The slide was air
dried, mounted with VECTASHIELDW mounting medium,
and examined under a DMI 4000 confocal fluorescence
microscope (Leica, Wetzlar, Germany). Morphological
assessment of apoptosis was performed as follows: bright-
green cells (FITC+/PI-), yellow cells (FITC+/PI+), and
birght-red cells (FITC-/PI+) were considered to early
apoptotic, late apoptotic (secondary necrotic), and nec-
rotic cells, respectively. A total of about 300 cells from
four randomly selected fields were counted, and the
number of apoptotic cells was expressed as a percentage
of the total number of cells scored.
Transmission electron microscopy (TEM) observation
The transmission electron microscopy (TEM) was utilized
for analyzing the ultra-structural images of nucleolus.
In brief, treated cells were collected by centrifugation,
samples were then fixed in 2.5% glutaraldehyde (Sigma
Co., Ltd., USA) for 24 h, washed in 0.1 M phosphate
buffer (pH 7.4), post-fixed in 1% osmium tetroxide
(Polyscience Co., Ltd., USA) in 0.1 M phosphate buffer
(pH 7.4), and subsequently dehydrated in increasing
concentrations of alcohol. The samples were impreg-
nated with prophylene oxide (Merck-Schuchardt Inc.,
Hohenbrunn, Germany) and embedded in epoxy resin
embedding media. After a light microscopic examination
of semi-thin sections and staining with 2% (w/v) uranyl
acetate and 1% (w/v) lead citrate, and then observed
with a JEM-1200EX II (Jeol, Japan) transmission electron
microscope.
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Collected cells were washed twice with ice-cold PBS
and re-suspended in 150 μL RIPA cell lysis buffer (Sigma-
Aldrich Co., St. Louis, MO, USA), mixed completely, incu-
bated on ice for 30 min, and followed by centrifugation
12,000 × g for 20 min at 4°C. Supernatants were then
stored at −80°C until use. Protein concentrations were
determined using the Bio-Rad Protein Assay (Bio-Rad
Laboratories, Hercules, CA). Equal proteins (30 μg · lane-1)
were separated on SDS-PAGE and transferred onto poly-
vinylidene difluoride (PVDF) membrane (Immobilion-P;
Millipore, Bedford, MA). Membranes were then blocked
with 5% nonfat milk, washed briefly, incubated with
primary antibodies at 4°C overnight, and then incubated
with corresponding HRP-conjugated secondary antibodies
for 1 h at room temperature. Protein bands were visual-
ized by incubating membranes with chemiluminescence
reagents before exposure to X-ray film.
DNA fragmentation assay
After treatment, cells were harvested in a 1.5 mL
Eppendorf tube, washed with PBS, and resuspended in
400 μL lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl,
10 mM ethylenediaminetetraacetic acid (EDTA), 1%Figure 1 Fluvastatin induced apoptosis in lymphoma cells. Lymphoma
lymphoma cells was analyzed by using annexin V (AV)-FITC/PI double stain
from A20 cells (A) and EL4 cells (C) were shown (bar = 75 μm). Apoptosis l
positive and AV-FITC/PI double positive cells) and total cells for A20 cells (B
separate experiments, *p < 0.05, **p < 0.01 versus resting cells.Sodium Dodecyl Sulfate (SDS), and 100 μg · mL-1 Pro-
teinase K) and incubated at 65°C overnight. 75 μL Po-
tassium acetate (8 M) was then added and the samples
were incubated at 4°C for 15 min. 750 μL chloroform
was added into the Eppendorf tube, which was then
mixed vigorously and centrifuged (12,000 × g) at room
temperature for 10 min. The supernatant was trans-
ferred into a new Eppendorf tube and 750 μL ethanol
was added, followed by overnight incubation of the
sample at −20°C. DNA was acquired by centrifugation
(12,000 × g, 10 min) of the sample, washed, dried, and
dissolved in 50 μL TE buffer (10 mM Tris–HCl, 1 mM
EDTA, pH 8.0). Five micrograms of DNA were analyzed
on 2.0% agarose gel.Statistical analysis
All data are presented as the mean ± SEM of at least
three separate experiments. Statistical analysis was per-
formed using one-way ANOVA followed by Dunnett's
multiple comparison test. Comparisons between two
groups were analyzed using the Student’s t-test. A p
value of less than 0.05 was considered to be statistically
significant.cells were incubated with fluvastatin (0–10 μM) for 24 h. Apoptosis of
ing and confocal laser scanning microscopy. Representative images
evels were evaluated by the ratio of apoptotic cells (AV-FITV alone
) and EL4 cells (D). Data are presented as mean ± SEM of three
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Fluvastatin induced apoptosis in lymphoma cells
Apoptosis in lymphoma cells treated with fluvastatin
was detected by using annexin V (AV)-FITC/PI double
staining and laser confocal fluorescence microscope.
Our results showed that the numbers of apoptotic cells
(AV-FITC alone positive and AV/PI double positive cells)
in both A20 and EL4 cells treated with fluvastatin were
greatly increased in a dose-dependent manner (Figure 1A
and C). Moreover, the statistic analysis showed that
apoptosis of lymphoma cells was significantly induced
by fluvastatin even at lowest concentration of 1.25 μM
(Figure 1B and D).Figure 2 Effects of fluvastatin on activation of apoptosis-related mole
24 h. (A and B) Expression of cleaved caspase-3 in A20 cells (A) and EL4 ce
caspase-3 were evaluated by the ratio of chemiluminescent signals betwee
in lower panel. Up panel showed the ratio of chemiluminescent signals be
three separate experiments, *p < 0.05, **p < 0.01 versus resting cells. (C an
examined by using Western blotting. Apoptosis levels were evaluated by the
images were shown in lower panel. Up panel showed the ratio of chemilumin
of three separate experiments, **p < 0.01 versus resting cells. (E) Activity of ca
are presented as mean ± SEM of three separate experiments, **p < 0.01 versuEffects of fluvastatin on activation of apoptosis-related
molecules
To further explore the molecular mechanism by which
fluvastatin induces apoptosis in lymphoma cells, the
activation of several apoptosis relevant molecules was
assessed by Western blotting. As shown in Figure 2A
and B, fluvastatin increased the expression of cleaved
caspase-3 in lymphoma cells in a dose-dependent manner
(p < 0.05). Moreover, fluvastatin greatly increased the ratio
of Bax and Bcl2 in lymphoma cells in a dose-dependent
manner (Figure 2C and D). The activity of caspase-3 was
also significantly increased in A20 cells exposed to
fluvastatin (Figure 2E). These results revealed that thecules. Lymphoma cells were incubated with fluvastatin (0–10 μM) for
lls (B) were examined by using Western blotting. Activation levels of
n cleaved caspase-3 and β-actin. Representative images were shown
tween cleaved caspase-3 and c Data are presented as mean ± SEM of
d D) Expression of Bax and Bcl2 in A20 cells (C) and EL4 cells (D) were
ratio of chemiluminescent signals between Bax and Bcl2. Representative
escent signals between Bax and Bcl2. Data are presented as mean ± SEM
spase-3 in A20 cells was evaluated by using caspase-3 activity kit. Results
s resting cells.
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and Bax was increased, but the activation of anti-
apoptotic molecule Bcl2 was decreased in fluvastatin-
treated lymphoma cells. In addition, increased activity of
caspase-3 was also observed in A20 cells treated with
fluvastatin.Detection of apoptosis and autophagy by TEM in
lymphoma cells
Previous study has demonstrated the present of autophagy
in apoptotic cells [17,18]. In the present study, to further
explore whether autophagy occurs during apoptotic
process of lymphoma cells treated by fluvastatin, the
transmission electron microscopy (TEM) was utilized
for analyzing the ultra-structural images of nucleolus.
As shown in Figure 3, autophagosome- or autophago-
some-like structures were not observed in unstimulated
lymphoma cells. In contrast, lymphoma cells treated
with fluvastatin showed autophagosomes and autolyso-
somes, in which the vacuolar content was degraded
(arrows). Furthermore, the features of apoptosis such as
chromatin condensation and apoptotic bodies were also
observed after treatment with fluvastatin at concentrations
of 2.5 μM (asterisks). These findings suggest that au-
tophagy might be involved in apoptosis of lymphoma
cells treated with fluvastatin.Figure 3 Detection of apoptosis and autophagy by TEM in lymphoma
24 h and analyzed by TEM. Arrows indicate autophagosomes. Asterisks indEffects of fluvastatin on activation of autophagy-related
molecules
The conversion of LC3-I into LC3-II is an essential step in
autophagosome formation, and the abundance of LC3-II
correlates with the number of autophagosomes [20,21].
To further explore the underlying mechanism for autoph-
agy in fluvastatin-treated lymphoma cells, we examined
the expression of LC3-I and LC3-II. As shown in Figure 4A
and B, fluvastatin greatly enhanced the expression of LC3-
II in A20 or EL4 lymphoma cells 24 h after treatment, in
parallel with unchanged or decreased expression of LC3-I,
respectively. Moreover, the expression ratio of LC3-II
and β-actin in lymphoma cells was significantly increased
by fluvastatin in a dose-dependent manner (p < 0.01).
To explore the time course, we incubated lymphoma cells
with fluvastatin at 2.5 μM for 12, 24 and 36 h, respectively.
Our results showed that fluvastatin also significantly in-
creased the expression ratio of LC3-II and β-actin in lymph-
oma cells in a time-dependent manner (Figure 4C and D,
p < 0.01). These results reveal that fluvastatin could induce
autophagy in lymphoma cells by activating LC3-II pathway.Fluvastatin induced apoptosis in lymphoma cells
through autophagy
We subsequently examined the relationship between
apoptosis and autophagy in lymphoma cells inducedcells. Lymphoma cells were incubated with fluvastatin at 2.5 μM for
icate nuclear condensation. Representative images are shown.
Figure 4 Effects of fluvastatin on activation of autophagy-related molecules. (A and B) Lymphoma cells were incubated with fluvastatin
(0–10 μM) for 24 h. Expression of LC3 in A20 cells (A) and EL4 cells (B) were examined by using Western blotting. Activation of autophagy was
evaluated by the ratio of chemiluminescent signals between LC3-II and β-actin. Representative images were shown in lower panel. Up panel showed
the ratio of chemiluminescent signals between LC3-II and β-actin. Data are presented as mean ± SEM of three separate experiments, **p < 0.01 versus
resting cells. (C and D) Lymphoma cells were incubated with fluvastatin (2.5 μM) for indicated periods. Expression of LC3 in A20 cells (C) and EL4 cells
(D) were examined by using Western blotting. Activation of autophagy was evaluated as described above. Representative images were shown
in lower panel. Up panel showed the ratio of chemiluminescent signals between LC3-II and β-actin. Data are presented as mean ± SEM of
three separate experiments, **p < 0.01 versus resting cells.
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at 2.5 μM for 24 h in the presence or absence of the
specific inhibitor of autophagy, 3-methyladenine. Activation
of caspase-3 was evaluated by the expression ratio of
cleaved caspase-3 and β-actin. As shown in Figure 5A,
fluvastatin markedly increased the expression of cleaved
caspase-3. However, fluvastatin-induced activation of cas-
pase-3 was significantly blocked by the addition of 3-MA
(p < 0.01), despite no significant changes was observed in
lymphoma cells treated with 3-MA alone compared with
resting cells. Western blotting analysis also showed that
fluvastatin-induced expression of LC3-II was significantly
suppressed by the addition of 3-MA in a dose-dependent
manner, which confirming the specific inhibition of au-
tophagy by 3-MA (Figure 5B). Taken together, autophagy
might contribute to apoptosis in lymphoma cells treated
with fluvastatin.
Fluvastatin-induced apoptosis and autophagy required
mevalonate pathways
To further examine the signaling mechanism for fluvas-
tatin-induced apoptosis and autophagy in lymphoma
cells, we incubated A20 cells with fluvastatin in thepresence or absence of mevalonate (Mev), geranylgeranyl
pyrophosphate ammonium salt (GGPP), farnesyl pyrophos-
phate ammonium salt (FPP), or coenzyme Q10 (CoQ10).
As shown in Figure 6A and B, the increases in expression
of cleaved caspase 3 and LC3-II regulated by fluvastatin
were markedly blocked by Mev, FPP, or GGPP, but not by
the addition of CoQ10. Furthermore, fluvastatin-induced
DNA fragmentation in A20 cells was also suppressed
by the addition of Mev, FPP, or GGPP (Figure 6C). These
results indicated that mevalonate pathways may con-
tribute to fluvastatin-mediated apoptosis and autophagy
in lymphoma cells.
Discussion
Increasing evidence from both in vitro and in vivo data
indicated that statins exhibit cytotoxicicy towards cancer
cells by inducing apoptosis in a cell type-dependent
manner. Recent studies have demonstrated the complex
relationship between autophagy and apoptosis in different
cell types [17,18]. However, the involvement of autophagy
in fluvastatin-induced apoptosis of malignant lymphoma
cells and the potential mechanism are still not clear. In
the present study, we revealed that fluvastatin induced
Figure 5 Fluvastatin induced apoptosis in lymphoma cells
through autophagy. (A) A20 Lymphoma cells were incubated with
fluvastatin (2.5 μM) in the presence or absence of 3-methyladenine
(3-MA, 1 mM) for 24 h. Expression of cleaved caspase-3 was analyzed
by Western blotting. Representative images were shown in lower
panel. Activation levels of caspase-3 were evaluated by the ratio of
chemiluminescent signals between cleaved caspase-3 and β-actin
(up panel). Data are presented as mean ± SEM of three separate
experiments, **p < 0.01. (B) A20 Lymphoma cells were incubated
with fluvastatin (2.5 μM) alone or in the presence of 3-MA (0.5-2 mM)
for 24 h, the expression of CL3 was then analyzed. Representative
images were shown in lower panel. Activation levels of LC3 were
evaluated by the ratio of chemiluminescent signals between LC3-II
and β-actin (up panel). Data are presented as mean ± SEM of three
separate experiments, **p < 0.01 versus fluvastatin group.
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through inhibition of metabolic products of the HMG-
CoA reductase reaction including mevalonate, farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate
(GGPP).
Many studies have reported that statins can induce
apoptosis in various cancer cells in a cell type-dependent
manner [7,9,11]. These reports are consistent with our
results showing that fluvastatin induced significant apop-
tosis in lymphoma cells in a dose-dependent manner,
which were examined by annexin V and PI double staining.
Increasing knowledge about apoptotic processes has
identified several targets which can be used as specific
cell death markers, including the changes in mitochondrial
membrane potential, cytochrome C, caspase members
and so on. The combination of released cytochrome C
and apoptotic protease activating factor-1 will active
caspase cascade and apoptosis [22,23]. Despite we did
not directly examined the release of cytochrome C, our
results demonstrated a dose-dependent increase in the
numbers of annexin V positive or annexin V/PI double
positive cells and the activation of caspase-3 in fluvastatin-
treated lymphoma cells (Figures 1 and 2). These results
indicating that fluvastatin in deed induces apoptotic
death of lymphoma cells. It is well known that the
apoptosis is mainly determined by a defective balance
among pro- and anti-apoptotic members of the Bcl-2
family, often related to resistance of lymphoma cells to
chemotherapy [24]. In our experimental condition, the
expression ratio of Bax and Bcl2 was significantly increased
in fluvastatin-treated lymphoma cells, indicating that
the pro-apoptotic signals were enhanced and the anti-
apoptotic signals were suppressed.
Autophagy induced by apoptotic stimuli was mostly
found in cancer cells or under the condition where
apoptosis is present [17,18]. In the present study, we
found that both apoptosis and autophagy were induced
by fluvastatin in lymphoma cells. TEM analysis confirmed
the presence of ultra-structural characteristics of apoptosis
and autophagy in lymphoma cells treated with fluvastatin
(Figure 6). The formation of autophagosome requires
Atg12 and Atg8 systems, which are tightly associated with
the expansion of autophagosomal membrane. Micro-
tubule-associated protein 1-light chain 3 (LC3) is the
mammalian homolog of the yeast protein Atg8. Upon
synthesis, LC3 is processed to its cytosolic form LC3-I
that is subsequently conjugated to the lipid phosphati-
dylethanolamine, generating the LC3-II form. Conjugation
to this lipid is required for its association with the autop-
hagosomal membrane. Which were consistent with our
data showing that the levels of LC3-II were significantly
increased in lymphoma cells treated with fluvastatin in a
dose- and/or time-dependent manner (Figure 4). Taken
together, both apoptosis and autophagy can be induced in
Figure 6 Fluvastatin-induced apoptosis and autophagy were
blocked by mevalonate, FPP, and GGPP. (A and B) A20
lymphoma cells were incubated with fluvastatin (2.5 μM) in the
presence or absence of mevalonate (Mev), farnesyl pyrophosphate
(FPP), geranylgeranyl pyrophosphate (GGPP), and coenzyme Q10
(CoQ10) for 24 h. The expression of cleaved caspase-3 and LC3 were
then detected by Western blotting. (A) Representative images were
shown. (B) Activation of cleaved caspase-3 (Bi) and LC3 (Bii) were
evaluated as described above. Data are presented as mean ± SEM of
three separate experiments, **p < 0.01 versus fluvastatin group. (C)
A20 lymphoma cells were incubated with fluvastatin (2.5 μM) in the
presence or absence of Mev (200 μM), FPP (10 μM), and GGPP (10 μM)
for 24 h. DNA fragmentation was then analyzed as described in the
Methods section. Left panel showed the representative image of DNA
fragmentation. The DNA fragmentation levels were evaluated by the
signal intensity ratio between degraded DNA bands versus intact
DNA bands (right panel). Data are presented as mean ± SEM of
three separate experiments, **p < 0.01 versus fluvastatin group.
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studies, the relationship between autophagy and apoptosis
is cell type- or condition-dependent. On the one hand,
autophagy is require for apoptosis in certain cell types with
indicated condition. For instance, inhibition of autophagy
abrogates tumor necrosis factor alpha induced apoptosis
in human T-lymphoblastic leukaemic cells [25]. On the
other hand, inhibition of apoptotic pathways cam induce
autophagy. For example, combination with inhibition of
caspase-3, inhibition of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) resulted in autophagy
[26]. However, our results revealed that fluvastatin-
induced activation of cleaved caspase-3 in lymphoma
cells was significantly blocked by the addition of specific
inhibitor of autophagy, 3-methyladenine (3-MA) (Figure 4),
indicating the requirement of autophagy for apoptosis
induced by fluvastatin.
Inhibition of HMG-CoA reductase by statins can lower
cholesterol by blocking the mevalonate pathway. Besides
reducing cholesterol biosynthesis, inhibition of mevalonate
by statins also leads to a reduction in the synthesis of
isoprenoids such as FPP and GGPP [27]. However, these
intermediates are involved in the positive modulation
of several non-steroid isoprenoids that are related to
antioxidant status, and a reduction in these non-steroid
isoprenoids induces oxidative stress [28,29]. Coenzyme
Q10 (CoQ10), an important intracellular antioxidant, has
membrane stabilizing effects and plays an important
role in cellular respiration and defending proteins from
oxidation [30]. In addition, dolichol is a polyprenol
compound that is synthesized by the general isoprenoid
pathway from acetate via mevalonate and farnesyl pyro-
phosphate and is broadly distributed in membranes.
Dolichol functions as a free-radical scavenger in the cell
membranes, and may interact with Vitamin E and poly
unsaturated fatty acids (PUFA) to form a highly matched
free-radical-transfer chain whose malfunctioning might
Qi et al. Cancer Cell International 2013, 13:111 Page 9 of 10
http://www.cancerci.com/content/13/1/111be involved in statin toxicity [31]. In view of these previous
studies, it is hypothesized that treatment with statin
increases intracellular oxidative stress by disrupting the
antioxidant defense system in certain transformed and
cancer cells, particularly by inhibiting biosynthesis of
isoprenoid antioxidants such as CoQ10 and dolichol.
This idea is further supported in part by our results
showing that both apoptosis and autophagy induced by
fluvastatin were greatly reversed by the addition of Mev,
FPP, and GGPP, although CoQ10 had minimal effect on
fluvastatin-induced apoptosis and autophagy (Figure 6).
In conclusion, the present study demonstrates that au-
tophagy contributes to fluvastatin-induced apoptosis in ma-
lignant lymphoma cells. Furthermore, these regulating
processes require the inhibition of metabolic products of the
HMG-CoA reductase reaction including mevalonate, farne-
syl pyrophosphate and geranylgeranyl pyrophosphate. This
study may provide new insight into molecular mechanism
by which fluvastatin induces apoptosis of lymphoma cells.
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